Cancer Research Annual Meeting 2010 Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papouli, E.
Right arrow Articles by Jiricny, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papouli, E.
Right arrow Articles by Jiricny, J.
[Cancer Research 64, 3391-3394, May 15, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

Dependence of the Cytotoxicity of DNA-Damaging Agents on the Mismatch Repair Status of Human Cells

Efterpi Papouli, Petr Cejka and Josef Jiricny

Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Mismatch repair (MMR) deficiency was reported to increase resistance of mammalian cells to killing by several genotoxic substances. However, although MMR-deficient cells are ~100-fold more resistant to killing by SN1 type methylating agents than MMR-proficient controls, the sensitivity differences reported for the other agents were typically <2-fold. To test whether these differences were linked to factors other than MMR status, we studied the cytotoxicities of mitomycin C, chloroethylcyclohexyl nitrosourea, melphalan, psoralen-UVA, etoposide, camptothecin, ionizing radiation, and cis-dichlorodiaminoplatinum (cisplatin) in a strictly isogenic system. We now report that MMR deficiency reproducibly desensitized cells solely to cisplatin.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
The mismatch repair (MMR) system plays an important role in the maintenance of genomic stability by correcting replication errors that escape processing by the proofreading activity of DNA polymerases and by controlling the fidelity of homologous recombination. Cells in which the MMR system has been inactivated display microsatellite instability, a phenotype identified in tumors of several different origins, both hereditary and sporadic (1) . MMR status has also been reported to influence the response of cells to a number of genotoxic agents and chemotherapeutics. However, whereas the link between MMR defects and resistance to N-methyl-N-nitrosourea, N-methyl-N'-nitro-N-nitrosoguanidine, temozolomide, 6-thioguanine, and cis-dichlorodiaminoplatinum (cisplatin) is generally accepted (2) , the effect of MMR status on the response of mammalian cells to other chemotherapeutic agents has been questioned. Thus, MMR-deficient cells were found to be more resistant to ionizing radiation (IR) in some laboratories (3 , 4) but not in others (5 , 6) . Loss of MMR has furthermore been reported to be associated with an increased resistance to topoisomerase (topo) poisons, especially the topo II inhibitors doxorubicin, epirubicin, and mitoxanthrone (7) , yet others described a sensitization to the same class of substances in the absence of MMR (8, 9, 10) . MMR-deficient clones derived from the human cancer cell lines HeLa and Raji were reported to be more sensitive to chloroethylcyclohexyl nitrosourea (CCNU) and mitomycin C (MMC; Refs. 11 , 12 ), and this phenotypic trait was observed also in some MMR-deficient tumor cell lines (11) . However, as in the case of IR, some cancer cell lines (11) and one MMR-deficient clone derived from an ovarian carcinoma cell line (13) displayed an increased resistance to CCNU. Because MMR-deficient cells have a mutator phenotype, their genomes are in a state of continuous flux during growth in tissue culture. Thus, clones derived from the same source could acquire slightly different phenotypes in different laboratories, and it is therefore formally possible that the discrepancies described above might be linked with these unknown phenotypic differences rather than with the MMR status of the cells. Given that many of the agents listed above are routinely used in cancer chemotherapy, the role of the MMR system in their efficacy must be elucidated, otherwise, their deployment in the treatment of tumors with microsatellite instability might have deleterious consequences. To address this issue while avoiding the above pitfalls, we studied the cytotoxicity of several DNA cross-linking agents, topo inhibitors, and IR in a strictly isogenic system in which the MMR status is regulated by doxycycline (Dox) and where the switching from MMR-proficient to -deficient status and vice versa does not involve clonal selection.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Cells.
The 293T L{alpha} cell line was established in our laboratory (14) . It was derived from the hMLH1-deficient human embryonic kidney 293T cells by stable transfection with a vector carrying the hMLH1 cDNA under the control of the inducible Tet-Off expression system. The cells were grown in DMEM with Eagle salts (Life Technologies, Inc., Gaithersburg, MD), supplemented with 10% Tet System approved fetal bovine serum (Clontech, Palo Alto, CA), 2 mM L-glutamine (Life Technologies, Inc.), 100 IU/ml penicillin, 100 µg/ml streptomycin (Life Technologies, Inc.), 100 µg/ml Zeocin (Invitrogen, San Diego, CA), and 300 µg/ml Hygromycin B (Roche Molecular Biochemicals, Basel, Switzerland). To obtain cells completely free of the MMR protein hMLH1 (293T L{alpha}–), the cells were transferred for at least 7 days to a medium containing 50 ng/ml Dox (Clontech). Fresh Dox was added every second day. To induce hMLH1 expression (293T L{alpha}+), the cells were transferred to a medium without Dox, the medium was changed the following day, and the cells were cultivated for at least 6 more days. Expression of hMLH1 in these cells fully restored MMR proficiency. All incubations were at 37°C in humidified 5% CO2 atmosphere. The cells were free of Mycoplasma contamination.

Genotoxic Treatments.
The cells were plated 1 day before treatment, and the exponentially growing attached cells were then treated either for 1 h with MMC (Sigma), melphalan (Sigma), CCNU (Lomustine; Bristol-Myers Squibb), or cisplatin (Fluka) or for 3 h with etoposide (Sigma) or camptothecin (Sigma) at the indicated concentrations at 37°C. After drug exposure, the cells were washed with PBS and incubated in fresh medium. Because of the short half-life (~1 h) of N-methyl-N'-nitro-N-nitrosoguanidine (Sigma) in aqueous solution, the medium was not changed after the treatment. In the case of psoralen treatment, 5000 cells were plated in 60-mm plates 1 day before treatment. The cells were then washed with PBS, incubated for 10 min in the dark at 37°C with 1 µM 4,5', 8-trimethyl-psoralen (Aldrich), in PBS/1 mM MgCl2, and then irradiated with 366 nm UV light (UV-A). They were then washed, fresh medium was added, and the cells were incubated for 5 days at 37°C. The medium was then removed, the cells were washed twice with PBS and stained with 1 ml of staining solution [0.1% crystal violet/1 mM MgCl2/10 mM potassium phosphate (pH 7.4)/250 mM sucrose] for 30 min. Cells were then rinsed and lysed with 10% acetic acid, and absorbance was measured at 595 nm. Cell viability was expressed relative to that of cells incubated with 4,5', 8-trimethyl-psoralen without UV irradiation.

MMR Assays.
In vitro MMR reaction was carried out as described previously (14) . Briefly, a circular 3188-bp DNA molecule containing a one nucleotide loop within the recognition site of BglII restriction endonuclease and a nick 5' from the mispair was incubated with nuclear protein extract. The substrate and unrepaired DNA molecule is resistant to BglII digestion, and successful MMR reaction reconstitutes the BglII site, making the DNA cleavable.

3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium Bromide (MTT) Assays.
A total of 2000 cells was plated in 96-well plates, treated with different concentrations of genotoxic agents the next day, and incubated for 4 or 5 more days. MTT (Sigma) solution was then added at a final concentration 0.9 mg/ml, and the plates were incubated for 5 h at 37°C. One volume of lysis solution was then added [20% SDS, 50% dimethylformamide (pH < 4.7)], and the plates were incubated overnight at 37°C. The solubilized formazan was quantified spectrophotometrically at 570 nm, using the Vmax microplate reader (Molecular Devices, Sunnyvale, CA). The absorbance values were plotted against drug concentrations, and IC50 values were calculated from the regression curve.

Clonogenic Assays.
Cells at ~50% confluency were either treated with CCNU, melphalan or cisplatin, or were irradiated (Philips PW2184/00Monitor SN4) with the indicated doses. They were then harvested and plated at various dilutions. At the same time, 300 untreated cells were plated to assess plating efficiency. Visible colonies were counted after 10 days.

Cell Cycle Analysis.
Cells, both attached and floating, were harvested, counted, washed with PBS, fixed with 70% ethanol, and stored up to 1 week at 4°C. The cells were then washed with PBS, incubated in PBS containing RNase A (100 µg/ml; Sigma) for 1 h at 37°C, stained with 20 µg/ml propidium iodide (Sigma), and incubated on ice in the dark for 30 min. DNA content was analyzed by Coulter EpicsFlow Cytometer (Beckman Coulter, Inc., Fullerton, CA).


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
The 293T L{alpha} cell line was derived from the hMLH1-deficient human embryonic kidney 293T cells by stable transfection with a vector carrying the hMLH1 cDNA under the control of the inducible Tet-Off expression system. In the absence of Dox, these cells express hMLH1 and are MMR proficient (293T L{alpha}+). When Dox is added to the medium, hMLH1 expression is shut off, and the cells become MMR deficient (293T L{alpha}–; Fig. 1ACitation ; Ref. 14 ). In this strictly isogenic setting, any differences in sensitivity of the 293T L{alpha}+ and 293T L{alpha}– cells to chemotherapeutic agents can be ascribed to the different MMR status of the cells because GeneChip analysis detected no significant differences in the transcriptomes of the 293T L{alpha}– and -L{alpha}+ cells, other than the change in hMLH1 mRNA levels (15) .



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A. in vitro mismatch repair (MMR) assay. The heteroduplex substrate containing a single mismatch (one extrahelical nucleotide) is refractory to cleavage with BglII (BglIIr). Repair of the mismatch regenerates the BglII cleavage site (BglIIs). The figure shows that the extracts of the 293T L{alpha}– cells are MMR deficient, whereas those of 293T L{alpha}+ cells are MMR proficient. See "Materials and Methods" for details. B, cytotoxicity induced in MMR-proficient 293T L{alpha}+ ({blacksquare}) and MMR-deficient 293T L{alpha}– cells ({square}) by alkylating agents and cisplatin. Each point represents the mean of three independent experiments with triplicate cultures. Bars represent SDs. Cell survival was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays. C, cell cycle distributions of MMR-proficient 293T L{alpha}+ and MMR-deficient 293T L{alpha}– cells after treatment (1 h) with an IC50 concentration of mitomycin C. Exponentially growing cells (C) or mitomycin C-treated cells were harvested 4, 8, 24, 31, and 72 h after treatment and cell cycle analysis was carried out by flow cytometry.

 
In our earlier study (14) , we could show that the MMR-proficient 293T L{alpha}+ cells were 125-fold more sensitive to killing by the SN1 type methylating agent N-methyl-N'-nitro-N-nitrosoguanidine (Table 1)Citation and arrested at the G2-M phase of the cell cycle. Recently, we could show that the checkpoint is ATR and CHK1 dependent (16) . Having shown that 293T L{alpha} cells retain intact DNA damage checkpoint pathways, we now examined the response of these cells to MMC, CCNU, melphalan, and psoralen-UVA, agents that form interstrand cross-links (ICLs), to cisplatin, which forms preferentially 1,2-GG and 1,2-AG intrastrand cross-links, to camptothecin and etoposide, representative inhibitors of topoisomerase I and II, respectively, and to IR.


View this table:
[in this window]
[in a new window]

  		Table 1 IC50 drug concentrations of mismatch repair-proficient (293T L{alpha}+) and mismatch repair-deficient (293T L{alpha}–) cells

The value marked with an asterisk is taken from Ref. 14 . The values represent the mean ± SD of three independent experiments done in triplicate.

 
The cytotoxicities of all of the above agents were first determined by MTT assays. The cells were exposed for 1 h to different concentrations of the reagents and their viability was measured 4 or 5 days later (see "Materials and Methods"). With the exception of cisplatin, the response of 293T L{alpha}+ and 293T L{alpha}– cells to the reagents was very similar (Fig. 1B)Citation . The IC50s (Table 1)Citation for the MMR-proficient and -deficient cells were 0.92 ± 0.15 and 0.87 ± 0.13 µM for CCNU, 468.5 ± 4.9 and 488 ± 2.8 nM for melphalan, 38.5 ± 8.3 and 46.6 ± 12.3 ng/ml for MMC, and 63.8 and 62 J/m2 for psoralen-UVA. In the case of cisplatin, the 293T L{alpha}+ cells were slightly more sensitive to killing by this drug than 293T L{alpha}– cells (3.3 ± 0.1 versus 6.7 ± 1.4), as seen with other human cell lines (17, 18, 19) . However, the contribution of the MMR system toward the cytotoxicity of this drug appears to be somewhat smaller than reported in other studies.

MTT assays detect viable cells in the cultures 4 or 5 days posttreatment but fail to identify arrested cells that may recover later. As the response of our cell pair to CCNU and melphalan was unexpected, inasmuch as MMR-deficient cells were anticipated to be more sensitive to these drugs than MMR-proficient ones (11) , we studied the long-term response of our cells to these drugs also in clonogenic assays. As shown in Table 1Citation , the IC50s determined by both assays were very similar, which implied that the toxicity differences observed in earlier studies were not linked to the MMR status of the cells, but were most likely clone and/or cell type dependent. This hypothesis was additionally confirmed by the finding that the magnitude and duration of a G2-M cell cycle arrest, induced by treatment with an IC50 concentration of MMC, was similar in both 293T L{alpha}+ and 293T L{alpha}– cells (Fig. 1C)Citation .

Treatment of cells with genotoxic agents generally gives rise to a plethora of different modifications in the DNA. Thus, drugs such as CCNU and melphalan generate monoadducts, primarily on guanines, as well as interstrand cross-links (ICLs) and MMC, causes ICLs, intrastrand cross-links, and oxidative damage that leads to base modifications. However, available evidence points to ICLs as the lesions responsible for the cytotoxicity of these drugs, and the same applies to trimethylpsoralen combined with UV light. The molecular mechanism of ICL repair has not been elucidated to date, but it is believed that a subset of proteins involved in nucleotide excision repair and recombination, together with polypeptides linked with Fanconi anemia, a clinical syndrome characterized by extreme sensitivity to DNA cross-linking agents, may participate in their detoxification. It is therefore not surprising that the toxicity of drugs generating ICLs may not be affected by the MMR status of the cell.

We next addressed the question whether MMR status modulates cellular response to topo poisons. When the 293T L{alpha}+ and 293T L{alpha}– cells were treated with the topo I inhibitor camptothecin or the topo II inhibitor etoposide, MTT assays (Fig. 2)Citation showed no notable differences in sensitivity between the MMR-deficient and -proficient cells (Table 1)Citation . Camptothecin and etoposide prevent the re-ligation of single- and double-strand breaks made in supercoiled DNA by topos I and II, respectively. MMR proteins have been reported to participate in recombination-mediated double-strand break repair (19) . However, judging by the lack of a differential response of the MMR-proficient and -deficient cells to topo inhibitors, the processing of camptothecin- or etoposide-stabilized breaks does not appear to involve the MMR system.



View larger version (8K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Cytotoxicity induced in mismatch repair-proficient 293T L{alpha}+ ({blacksquare}) and mismatch repair-deficient 293T L{alpha}– cells ({square}) by the topoisomerase inhibitors camptothecin and etoposide. Each point represents the mean of three independent experiments with triplicate cultures. Bars represent SDs. Cell survival was determined by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assays.

 
IR also generates many different types of modifications in DNA. Base damage represents ~80% of these modifications, but cytotoxicity of IR is ascribed to the production of single-strand breaks and, primarily, double-strand breaks. The repair of these latter lesions is accomplished through homologous recombination or nonhomologous end-joining (21) . MMR has been implicated in both processes, but the 293T L{alpha}+ and 293T L{alpha}– cells displayed comparable sensitivities to IR (Fig. 3)Citation , as described also by others using different matched MMR-positive and -negative cell lines (5 , 12) . Thus, although MMR-deficient cell lines have been reported by some laboratories to be either slightly more (3 , 4) or less (6) resistant to killing by IR than matched MMR-proficient ones, our present results suggest that these differences were unlikely to be linked with the differential MMR status of the cells.



View larger version (9K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Cytotoxicity induced in mismatch repair-proficient 293T L{alpha}+ ({blacksquare}) and mismatch repair-deficient 293T L{alpha}– cells ({square}) by ionizing radiation. Each point represents the mean of three independent experiments with triplicate cultures. Bars represent SDs. Cell survival was determined by clonogenic assays.

 
The cells described in this study switch their MMR capability upon Dox addition/withdrawal within only very few cell divisions, and the change of MMR status is not accompanied by noticeable cell death. Thus, where differences in survival to genotoxic stress are observed in this system, they can only be ascribed to the different MMR status of the cells. In this system, inactivation of the MMR system was shown to render human cells slightly more resistant to killing by cisplatin. Coupled with the results of our earlier study, where the 293T L{alpha}– cells were found to be >100-fold more resistant to killing by N-methyl-N'-nitro-N-nitrosoguanidine than 293T L{alpha}+ cells (14) , our data provide clear evidence for the involvement of the MMR system in the cytotoxicity of these two substances and thus fully support the findings of others. In contrast, we failed to detect significant differences in the response of our cells to cross-linking agents, topo poisons, and IR. Thus, the variable response of the other cell systems to these reagents is unlikely to have been associated solely with the MMR status of the cells and must have involved other factors.

The substances investigated in the present study are in frequent use in the therapy of a variety of cancers. The emergence of drug resistance during cancer therapy represents a serious complication, and it is important that its basis is well understood. It is hoped that the isogenic system used in this study will prove useful not only in the elucidation of the molecular mechanisms of drug resistance but also in the identification of substances capable of preferential killing of MMR-deficient cells. Given that a substantial proportion of cancers displays microsatellite instability, these therapeutics are urgently needed.


   ACKNOWLEDGMENTS
 
We thank Primo Schär for help with the irradiations, Elda Cannavó for assistance with the cisplatin experiments, Katja Bärenfaller for the substrate for the MMR assay, and Eva Niederer in the Flow Cytometry Laboratory of the Institute of Biomedical Engineering of the Eidgenössische Technische Hochschule (ETH) and the University of Zürich for help with the fluorescence-activated cell sorting analyses.


   FOOTNOTES
 
Grant support: European Community Grant QLG1-CT-2000-01230 (E. Papouli and J. Jiricny) and Swiss National Science Foundation Grant 3100-068182.02 (P. Cejka and J. Jiricny).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Josef Jiricny. Phone: 41-1-634-8910; Fax: 41-1-634-8904; E-mail: jiricny{at}imr.unizh.ch

Received 2/16/04. Revised 4/ 1/04. Accepted 4/ 6/04.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Jiricny J, Marra G DNA repair defects in colon cancer. Curr Opin Genet Dev, 13: 61-9, 2003.[CrossRef][Medline]
  2. Karran P Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis (Lond.), 22: 1931-7, 2001.[Abstract/Free Full Text]
  3. Fritzell JA, Narayanan L, Baker SM, et al Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res, 57: 5143-7, 1997.[Abstract/Free Full Text]
  4. Zeng M, Narayanan L, Xu XS, Prolla TA, Liskay RM, Glazer PM Ionizing radiation-induced apoptosis via separate Pms2- and p53-dependent pathways. Cancer Res, 60: 4889-93, 2000.[Abstract/Free Full Text]
  5. Yan T, Schupp JE, Hwang HS, et al Loss of DNA mismatch repair imparts defective cdc2 signaling and G2-arrest responses without altering survival after ionizing radiation. Cancer Res, 61: 8290-7, 2001.[Abstract/Free Full Text]
  6. Franchitto A, Pichierri P, Piergentili R, Crescenzi M, Bignami M, Palitti F The mammalian mismatch repair protein MSH2 is required for correct MRE11 and RAD51 relocalization and for efficient cell cycle arrest induced by ionizing radiation in G2 phase. Oncogene, 22: 2110-20, 2003.[CrossRef][Medline]
  7. Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D Resistance to topoisomerase poisons due to loss of DNA mismatch repair. Int J Cancer, 93: 571-6, 2001.[CrossRef][Medline]
  8. Pichierri P, Franchitto A, Piergentili R, Colussi C, Palitti F Hypersensitivity to camptothecin in MSH2-deficient cells is correlated with a role for MSH2 protein in recombinational repair. Carcinogenesis (Lond.), 22: 1781-7, 2001.[Abstract/Free Full Text]
  9. Jacob S, Aguado M, Fallik D, Praz F The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res, 61: 6555-62, 2001.[Abstract/Free Full Text]
  10. Fedier A, Ruefenacht UB, Schwarz VA, Haller U, Fink D Increased sensitivity of p53-deficient cells to anticancer agents due to loss of Pms2. Br J Cancer, 87: 1027-33, 2002.[CrossRef][Medline]
  11. Aquilina G, Ceccotti S, Martinelli S, Hampson R, Bignami M N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea sensitivity in mismatch repair-defective human cells. Cancer Res, 58: 135-41, 1998.[Abstract/Free Full Text]
  12. Aquilina G, Crescenzi M, Bignami M Mismatch repair, G2-M cell cycle arrest and lethality after DNA damage. Carcinogenesis (Lond.), 20: 2317-26, 1999.[Abstract/Free Full Text]
  13. Aquilina G, Ceccotti S, Martinelli S, et al Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. Clin Cancer Res, 6: 671-80, 2000.[Abstract/Free Full Text]
  14. Cejka P, Stojic L, Mojas N, et al Methylation-induced G2-M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J, 22: 2245-54, 2003.[CrossRef][Medline]
  15. di Pietro M, Marra G, Cejka P, et al Mismatch repair-dependent transcriptome changes in human cells treated with the methylating agent MNNG. Cancer Res, 63: 8158-66, 2003.[Abstract/Free Full Text]
  16. Stojic L, Mojas N, Cejka P, et al. Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase. Genes Dev 2004, in press.
  17. Brown R, Hirst GL, Gallagher WM, et al hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 15: 45-52, 1997.[CrossRef][Medline]
  18. Fink D, Zheng H, Nebel S, et al In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res, 57: 1841-5, 1997.[Abstract/Free Full Text]
  19. Drummond JT, Anthoney A, Brown R, Modrich P Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line. J Biol Chem, 271: 19645-8, 1996.[Abstract/Free Full Text]
  20. Villemure JF, Abaji C, Cousineau I, Belmaaza A MSH2-deficient human cells exhibit a defect in the accurate termination of homology-directed repair of DNA double-strand breaks. Cancer Res, 63: 3334-9, 2003.[Abstract/Free Full Text]
  21. Kanaar R, Hoeijmakers JH, van Gent DC Molecular mechanisms of DNA double strand break repair. Trends Cell Biol, 8: 483-9, 1998.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
R. P. Topping, J. C. Wilkinson, and K. D. Scarpinato
Mismatch Repair Protein Deficiency Compromises Cisplatin-induced Apoptotic Signaling
J. Biol. Chem., May 22, 2009; 284(21): 14029 - 14039.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
Z. Hong, J. Jiang, K. Hashiguchi, M. Hoshi, L. Lan, and A. Yasui
Recruitment of mismatch repair proteins to the site of DNA damage in human cells
J. Cell Sci., October 1, 2008; 121(19): 3146 - 3154.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Rodriguez, L. T. Hansen, G. Phear, J. Scorah, M. Spang-Thomsen, A. Cox, T. Helleday, and M. Meuth
Thymidine Selectively Enhances Growth Suppressive Effects of Camptothecin/Irinotecan in MSI+ Cells and Tumors Containing a Mutation of MRE11
Clin. Cancer Res., September 1, 2008; 14(17): 5476 - 5483.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in GastroenterologyHome page
J. M. Carethers
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 33 - 42.
[Abstract] [PDF]

Home page
 CarcinogenesisHome page
M. Reynolds and A. Zhitkovich
Cellular vitamin C increases chromate toxicity via a death program requiring mismatch repair but not p53
Carcinogenesis, July 1, 2007; 28(7): 1613 - 1620.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. P. Cahill, K. K. Levine, R. A. Betensky, P. J. Codd, C. A. Romany, L. B. Reavie, T. T. Batchelor, P. A. Futreal, M. R. Stratton, W. T. Curry, et al.
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
Clin. Cancer Res., April 1, 2007; 13(7): 2038 - 2045.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. Reynolds, L. Stoddard, I. Bespalov, and A. Zhitkovich
Ascorbate acts as a highly potent inducer of chromate mutagenesis and clastogenesis: linkage to DNA breaks in G2 phase by mismatch repair
Nucleic Acids Res., January 28, 2007; 35(2): 465 - 476.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. D. Kennedy and A. D. D'Andrea
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
J. Clin. Oncol., August 10, 2006; 24(23): 3799 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M Carethers
Prospective evaluation of fluorouracil chemotherapy based on the genetic makeup of colorectal cancer.
Gut, June 1, 2006; 55(6): 759 - 761.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hunter, R. Smith, D. P. Cahill, P. Stephens, C. Stevens, J. Teague, C. Greenman, S. Edkins, G. Bignell, H. Davies, et al.
A Hypermutation Phenotype and Somatic MSH6 Mutations in Recurrent Human Malignant Gliomas after Alkylator Chemotherapy.
Cancer Res., April 15, 2006; 66(8): 3987 - 3991.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
V. O'Brien and R. Brown
Signalling cell cycle arrest and cell death through the MMR System
Carcinogenesis, April 1, 2006; 27(4): 682 - 692.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Komatsu, K. Hiyama, K. Tanimoto, M. Yunokawa, K. Otani, M. Ohtaki, E. Hiyama, J. Kigawa, M. Ohwada, M. Suzuki, et al.
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
Mol. Cancer Ther., March 1, 2006; 5(3): 767 - 775.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
E. Peterson-Roth, M. Reynolds, G. Quievryn, and A. Zhitkovich
Mismatch Repair Proteins Are Activators of Toxic Responses to Chromium-DNA Damage
Mol. Cell. Biol., May 1, 2005; 25(9): 3596 - 3607.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Fukushima, Y. Katayama, T. Watanabe, A. Yoshino, A. Ogino, T. Ohta, and C. Komine
Promoter Hypermethylation of Mismatch Repair Gene hMLH1 Predicts the Clinical Response of Malignant Astrocytomas to Nitrosourea
Clin. Cancer Res., February 15, 2005; 11(4): 1539 - 1544.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papouli, E.
Right arrow Articles by Jiricny, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papouli, E.
Right arrow Articles by Jiricny, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online